Peter Ballard

2024-12-10T15:08:53+00:00

Meet The Team

Dr Peter Ballard

Dr Peter Ballard

PhD

Peter is a senior drug metabolism and pharmacokinetic (DMPK) expert with extensive experience in global discovery and development small molecule projects across multiple therapeutic areas including oncology, infection and cardiovascular. He has a proven track record of international project delivery from early drug discovery through to clinical development and compound registration from 40 years in the pharmaceutical industry with GSK, Astrazeneca and as an independent consultant. He has maintained a high academic profile with more than 30 publications in peer reviewed journals and presentations at international conferences. Peter has a keen analytical mind and a pragmatic approach to understanding  and resolving DMPK issues.

Jane Stewart

2024-06-12T14:00:35+01:00

Meet The Team

Dr Jane Stewart

Dr Jane Stewart

PhD, ERT, BVM&S, MRCVS

Jane is a senior toxicologist with world leading expertise in reproductive toxicology and the safety assessment of pharmaceuticals. Jane is renowned for her expertise in problem solving for general and reproductive toxicology as well as in the investigation of endocrine effects and carcinogenesis. Jane has authored numerous pregnancy labels and has helped draft international testing guidelines for pharmaceuticals. Jane is a PhD qualified veterinarian with a degree in pathological sciences.  Jane is known for her analytical mindset and ability to identify and resolve key issues.

William O’Brien

2024-02-19T16:50:32+00:00

Meet The Team

William O'Brien

William O’Brien

MA, MBA

William is a specialist R&D tax and finance advisor.  A seasoned leader, he has worked across a wide range of industries including Biotech, Medical Devices, Formula One, Defence and Finance. William has a degree in Neurophysiology from the University of Cambridge and an MBA from Manchester Business School.  William is a natural fit for ApconiX as he began his career working as a scientist at the Babraham Institute near Cambridge, using patch clamp and fluorescence imaging to study the role of GTP binding proteins in exocytosis.

Dr Kimberly Rockley

2024-12-12T09:57:49+00:00

Meet The Team

Dr Kimberley Rockley

Dr Kimberly Rockley

PhD

Kimberly Rockley leads the microelectrode (MEA) hiPSC-methods team and conducts MEA seizure liability studies for clients. Kim developed our iSLA (in vitro seizure liability assay) for which she has received a number of accolades including the BioNow Rising Star award in 2022. She holds a PhD in Pharmacy from Durham University where she used novel in vitro methods to investigate anthracycline-induced cardiotoxicity and its mitigation by perturbation of angiotensin signalling. Kim is passionate about the use of in vitro techniques to improve preclinical safety and reduce animal testing.

Ian Slater

2024-06-12T14:42:38+01:00

Meet The Team

Ian Slater

Ian Slater

MSc

Ian is an experienced toxicology Study Director and Study Monitor with expertise in GLP and non-GLP toxicology studies across diverse therapy areas.  He has extensive experience in working with CROs gained during his more than 20 years at AstraZeneca.  Ian was Chair of the Study Director Workshop of the British Toxicology Society from 2011-2015, providing a forum for the sharing of good practice and supporting the development of junior toxicologists.  Ian is a practical and pragmatic toxicologist who brings his wealth of experience to the design, conduct, delivery and reporting of toxicology studies.

Björn Dahl

2024-12-12T09:23:37+00:00

Meet The Team

Dr Bjorn Dahl

Björn Dahl

PhD ERT

Björn is a very experienced toxicologist with  more than 28 years of discovery and development  experience gained mainly in AstraZeneca.  Björn has worked across multiple therapy areas and has particular experience in the Cardiovascular, Renal and Metabolism therapy areas.  He has been directly involved in bringing over 35 new candidate drugs to clinical trials and 4 to marketing approval.  Björn was co-chair of the EFPIA Preclinical Development Expert Working Group until 2018 and was EFPIA topic lead on the ICH S11 Expert Working Group on nonclinical safety testing of paediatric medicines.  Björn brings his judgement, wisdom and problem-solving skills to the design and delivery of nonclinical strategies.

Steffen Ernst

2024-12-12T09:29:48+00:00

Meet The Team

steffen new | ApconiX

Dr Steffen Ernst

MD PhD MBA DABT ERT(BTS)

Steffen is an experienced discovery/regulatory toxicologist and patient safety physician with over 20 years of experience in non-clinical drug safety and clinical patient safety/pharmacovigilance gained in Big Pharma and small companies.  He holds patents to marketed oncology and immunological products and has been directly involved in bringing over 50 new candidate drugs to clinical trials and 9 to marketing approval.  Steffen is the European Review Editor of the Journal of Applied Toxicology (Wiley). Black belt trained in Lean Sigma, Steffen also gained an MBA from Heriot Watt University in Edinburgh. Steffen brings his expertise from working in both nonclinical and clinical roles to offer pragmatic and strategic input and solutions to projects.

Phumzile Sikakana

2024-12-12T10:29:36+00:00

Meet The Team

Phumzile Sikakana

Phumzile Sikakana

MSc

Phum has worked within the Safety Science Team at ApconiX for more than 6 years and has a proven track record of producing Target Safety Assessments. After studying Biomedical Sciences at Cardiff University, she completed her Master’s degree at Sheffield University. Phum is passionate about data analysis and applying her strong scientific background to Target Safety Assessments. Phum looks forward to using her communication skills and growing experience to build new client relationships.

Karen Jones

2024-06-12T14:44:47+01:00

Meet The Team

Dr Karen Jones

Dr Karen Jones

PhD

Karen is a Senior Research Scientist with over 10 years experience in the pharmaceutical industry within the early drug discovery setting. Karen’s area of expertise is in the development of Ion Channel and GPCR assays which are used for compound screening in various formats from small scale bespoke experiments up to large scale fully automated screens.  Karen is skilled at problem solving and has a proven track record of delivery with difficult targets leading to publications in peer reviewed journals.

Guy Healing

2024-12-12T09:41:08+00:00

Meet The Team

Dr Guy Healing

Dr Guy Healing

PhD, ERT, FBTS

Guy is an experienced senior toxicologist with expertise in general toxicology and the safety assessment of pharmaceuticals.  As a manager of pre-clinical Study Monitors and Study Directors, he is an expert in study design, conduct and reporting developed over 25 years in a complex global environment, with particular expertise in infusion technology. He has served on the BTS Executive Committee for 10 years, was until recently a Panel member for the UK Register of Toxicologists and has over 40 publications in peer reviewed journals.   Guy brings a pragmatic and collaborative approach to designing and delivering nonclinical studies to time, quality and cost.

Go to Top